Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions

Journal of Dermatological Science

Volumn 34, Issue 3, 2004, Pages 209-219

  Obata, Chikage ^a   Zhang, Manxin ^a   Moroi, Yoichi ^a   Hisaeda, Hajime ^a   Tanaka, Keiji ^b   Murata, Shigeo ^b   Furue, Masutaka ^a   Himeno, Kunisuke ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Dendritic cells; Formalin; Immunotherapy; Interleukin 12; PA28; Tumor

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENE TRANSFER; INTERFERON PRODUCTION; MELANOMA B16; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; BONE MARROW CELLS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; FEMALE; FIXATIVES; FORMALDEHYDE; INTERFERON TYPE II; INTERLEUKIN-12; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEINS; SKIN NEOPLASMS; SPLEEN; TUMOR CELLS, CULTURED;

EID: 2142764370     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2004.02.003     Document Type: Article

References (38)

1. Offringa R., Van den Burg S.H., Ossendorp F., Toes R.E., Melief C.J. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 12:2000;576-582
2. Houghton A.N., Gold J.S., Blachere N.E. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13:2001;134-140
3. Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., Todryk S. Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 51:2002;351-357
4. Huang A.Y., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. Role of bone-marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 264:1994;961-965
5. Albelt M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89
6. Sigal L.J., Crotty S., Andino R., Rock K.L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogeneous antigen. Nature. 398:1999;77-80
7. Strome S.E., Voss S., Wilcox R., Wakefield T.L., Tamada K., Flies D., et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62:2002;1884-1889
8. Nishitani M.A., Sakai T., Ishii K., Zhang M., Nakano Y., Nitta Y., et al. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells. Cancer Gene Ther. 9:2002;156-163
9. Fields R.C., Shimizu K., Mule J.J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9482-9487
10. Li M., Davey G.M., Sutherland R.M., Kurts C., Lew A.M., Hirst C., et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J. Immunol. 166:2001;6099-6103
11. Kotera Y., Shimizu K., Mule J.J. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 61:2001;8105-8109
12. Gallucci S., Lolkema M., Matzinger P. Natural adjutants: endogenous activators of dendritic cells. Nat. Med. 5:1999;1249-1255
13. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191:2000;423-434
14. Åhrén C., Jertborn M., Svennerholm A.M. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect. Immun. 66:1998;3311-3316
15. Raghavan M., Hjulstrom M., Holmgren J., Svennerholm A.M. Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines. Infect. Immun. 70:2002;6383-6388
16. Shrayer D.P., Kouttab N., Maizel A., Wanebi H., Hearing V.J., Gersten D.M. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Int. J. Cancer. 53:1993;696-702
17. Merk O., Speit G. Significance of formaldehyde-induced DNA-protein crosslinks for mutagenesis. Environ. Mol. Mutagen. 32:1998;260-268
18. Nakao H., Umebayashi C., Nakata M., Nishizaki Y., Noda K., Okano Y., et al. Formaldehyde-induced shrinkage of rat thymocytes. J. Pharmacol. Sci. 91:2003;83-86
19. Szende B., Tyihak E., Szokan G., Katay G. Possible role of formaldehyde in the apoptotic and mitotic effect of 1-methyl-ascorbigen. Pathol. Oncol. Res. 1:1995;38-42
20. Tyihak E., Bocsi J., Fimar F., Racz G., Szende B. Formaldehyde promotes and inhibits the proliferation of cultured tumour and endothelial cells. Cell Prolif. 34:2001;135-141
21. Orlando V., Paro R. Mapping polycomb-repressed domains in the bithorax complex using in vivo formaldehyde cross-linked chromatin. Cell. 75:1993;1187-1198
22. Wolkers M.C., Stoetter G., Vyth-Dreese F.A., Schmacher T.N. Pedundancy of direct priming and cross-priming in tumor-specific CD8 (+) T cell responses. J. Immunol. 167:2001;3577-3584
23. Tanaka K., Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol. Rev. 163:1998;161-176
24. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class molecules. Cell. 78:1994;761-771
25. Murata S., Udono H., Tanahashi N., Hamada N., Watanabe K., Adachi K., et al. Immunoproteasome assembly and antigen presentation in mice lacking both PA28α and PA28β EMBO J. 20:2001;5898-5907
26. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods. 223:1999;77-92
27. Sakai T., Hisaeda H., Nakano Y., Ishikawa H., Maekawa Y., Ishii K., et al. Gene gun-mediated delivery of an interleukin-12 expression plasmid protects against infections with the intracellular protozoan parasites Leishmania major and Trypanosoma cruzi in mice. Immunology. 99:2000;615-624
28. Rakhmilevich A.L., Turner J., Ford M.J., McCabe D., Sun W.H., Sondel P.M., Grota K., et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl. Acad. Sci. U.S.A. 93:1996;6291-6296
29. Nanni P., Rossi I., De Giovanni C., Landuzzi L., Nicoletti G., Stoppacciaro A., et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastasis. Cancer Res. 58:1998;1225-1230
30. Landay A., Jennings C., Forman M., Raynor R. Whole blood method for simultaneous detection of surface and cytoplasmic antigens by flow cytometry. Cytometry. 14:1993;433-440
31. Macey M.G., McCarthy D.A. Quantitation of adhesion molecules and other function-associated antigens on human peripheral blood leucocytes. Cytometry. 14:1993;898-908
32. Rovere P., Vallinoto A., Bondanza A., Crosti M.C., Rescigno M., Ricciardi-Castagnoli P., et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol. 161:1998;4467-4471
33. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 425:2003;516-521
34. + CTL responses in vitro. J. Clin. Invest. 98:1996;715-722
35. + CTL. J. Immunol. 167:2001;3687-3691
36. Rakhmilevich A.L., Timmins J.G., Janssen K., Pohlmann E.L., Sheehy M.J., Yang N.S. Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J. Immunother. 22:1999;135-144
37. Kloetzel P.M. Antigen processing by the proteasome. Nat. Rev. 2:2001;179-187
38. Van Hall T., Sijts A., Camps M., Offringa R., Melief C., Kloetzel P.M., et al. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med. 192:2000;483-494